Analyst Price Targets — NVS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 26, 2026 12:09 pm | Thibault Boutherin | Morgan Stanley | $170.00 | $149.70 | TheFly | Novartis price target raised to $170 from $143 at Morgan Stanley |
| December 10, 2025 11:16 am | — | HSBC | $112.00 | $131.01 | TheFly | Novartis price target raised to $112 from $106 at HSBC |
| December 3, 2025 11:33 am | — | Morgan Stanley | $143.00 | $132.28 | TheFly | Novartis price target raised to $143 from $136 at Morgan Stanley |
| October 29, 2025 3:42 pm | Wan Nurhayati | CFRA | $126.00 | $123.33 | StreetInsider | Novartis (NVS) PT Raised to $126 at CFRA |
| October 30, 2024 8:48 am | Etzer Darout | BMO Capital | $120.00 | $109.91 | StreetInsider | Novartis (NVS) PT Raised to $120 at BMO Capital |
| September 5, 2024 4:27 am | James Quigley | Goldman Sachs | $121.00 | $119.38 | TheFly | Novartis downgraded to Neutral from Buy at Goldman Sachs |
| July 19, 2024 9:06 am | Etzer Darout | BMO Capital | $118.00 | $106.13 | StreetInsider | Novartis (NVS) PT Raised to $118 at BMO Capital |
| April 23, 2024 1:11 pm | Wan Nurhayati | CFRA | $108.00 | $97.27 | StreetInsider | Novartis (NVS) PT Raised to $108 at CFRA |
Latest News for NVS
NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, strengthening its nephrology portfolio.
Besides Wall Street's top-and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
The Dividend Income Accelerator Portfolio emphasizes high-quality companies with sustainable dividends, strong balance sheets, and attractive valuations to optimize risk-adjusted returns. I prioritize a diversified mix of ETFs and individual stocks across sectors, balancing dividend income, growth, and capital appreciation while mitigating downside risk. Key metrics include a 3.75% weighted average dividend yield,…
Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net margins. Teva Pharmaceutical Industries is executing a turnaround focused on biosimilars and high-growth innovative assets.
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for NVS.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.